Team uncovers mechanism, and possible treatment, for immune suppression in liver disease

April 13, 2014

The mechanism which underlies the susceptibility of liver disease patients to life-threatening infection has been uncovered by Wellcome Trust-funded medical scientists, who have also suggested a possible treatment to reverse immune suppression in these patients.

Liver disease, or , is currently the fifth leading cause of death in the UK. Cirrhosis patients are more than five times more likely to pick up infections in hospital than patients with other chronic conditions, due to reduced immunity which is a well-recognised feature of the disease.

In a study published today in Nature Medicine, researchers at UCL propose that the underlying cause of hyper susceptibility to infection in cirrhosis patients is due to the over production of the lipid hormone prostaglandin E2 (PGE2). This hormone prevents white blood cells from ingesting bacteria and killing them.

In the study, 75 blood samples were taken from patients at hospitals including University College Hospital, Royal Free Hospital, Royal London Hospital, St Mary's Hospital and the Hospital Clinic of Barcelona.

Researchers also found that a decreased concentration globular blood protein albumin, which catalyses the inactivation of PGE2 in patients was contributing to low immunity.

The authors of the study have therefore suggested that cirrhosis patients should receive albumin infusions to reverse in .

The research was carried out by lead author Professor Derek Gilroy, Wellcome Trust Senior Research Fellow at UCL in collaboration with consultant hepatologist Dr Alistair O'Brien.

Professor Gilory said: "A defective was first observed in cirrhosis 30 years ago, and infection is most common cause of death in cirrhosis patients. However, the precise factors that cause reduced immunity have up until now been unknown.

"Our research has uncovered a powerful mechanism for immune suppression in cirrhosis patients and also proposes a relatively simple and safe treatment."

Dr O'Brien added: "We have discovered that the immune system of patients with advanced liver disease can be boosted for at least 24 hours by infusing albumin into a vein which reduces PGE2's effects. This safe process is currently given when patients need extra fluid, for example those with kidney damage.

"We propose that albumin be given daily to improve cirrhosis patients' immune systems and therefore prevent infection. We hope that this will save lives and reduce health-care costs and we intend to investigate this in a large scale clinical trial."

The researchers plan to carry out a clinical trial looking at the ability of albumin to reverse immune suppression in starting this summer. The trial is supported by the Wellcome Trust.

Explore further: Hepatitis C remains major problem for HIV patients despite antiretroviral therapy

More information: Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2, Nature Medicine, dx.doi.org/10.1038/nm.3516

Related Stories

Hepatitis C remains major problem for HIV patients despite antiretroviral therapy

March 17, 2014
A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that the risk of hepatitis C-associated serious liver disease persists in HIV patients otherwise benefitting from ...

Screening for liver cancer in patients with cirrhosis

April 1, 2014
In a systematic review and meta-analysis of 47 studies with 15,158 patients, Amit Singal (University of Texas Southwestern Medical Center) and colleagues found that patients with cirrhosis who underwent surveillance (via ...

Coffee consumption reduces mortality risk from liver cirrhosis

April 2, 2014
New research reveals that consuming two or more cups of coffee each day reduces the risk of death from liver cirrhosis by 66%, specifically cirrhosis caused by non-viral hepatitis. Findings in Hepatology, a journal published ...

New data reveals positive outcomes for hepatitis C transplant patients

April 11, 2014
New research announced at the International Liver Congress 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).

The economic cost of advanced liver disease

November 7, 2011
Health care costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study.

Research tackles liver transplant failure

November 7, 2013
The re-infection of transplanted livers with hepatitis C virus (HCV) – which can irreparably damage the new organ - could be halted by administering a drug which blocks the virus entering the liver, research from the University ...

Recommended for you

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

Vaccines protect fetuses from Zika infection, mouse study shows

July 13, 2017
Zika virus causes a mild, flu-like illness in most people, but to pregnant women the dangers are potentially much worse. The virus can reduce fetal growth, cause microcephaly, an abnormally small head associated with brain ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.